A patient from Mauritius with relapsed aggressive non-Hodgkin’s lymphoma travelled to India for an indigenously manufactured CAR-T cell therapy by ImmunoACT, a treatment that would have cost millions of dollars in the United States. His story is part of a quiet but growing trend: ImmunoACT has now treated close to 60 patients from 20+ countries …



